Overview / Wet lab and cell therapy

Wet lab and cell therapy

I engineer and assay primary human NK and CD8 T cells, design high-parameter flow cytometry panels, and run the preclinical models behind my analyses. My research looks at why NK and CD8 T cells lose function in tumours, and how to make cell therapies more effective.

flow cytometry
40+ colours
engineered in primary cells
NK, CD8
sole-PI grant
€100k

Techniques

Flow cytometry
Spectral (Cytek Aurora, Sony ID7000) and conventional cytometry (BD LSRFortessa, FACSymphony); 40+ colour panel design and validation; FACS sorting (BD FACSAria, Sony SH800); high-dimensional analysis (FlowSOM, UMAP, Spectre); core-facility training and support.
Cell engineering
CRISPR knock-out and knock-in in primary human NK and CD8 T cells; lentiviral and adenoviral overexpression; electroporation; CAR-NK and CAR-T; primary NK and T cell isolation and expansion; engineered and reporter cell lines.
Functional assays
Cytotoxicity by flow, luciferase and LDH, real-time killing (xCELLigence, IncuCyte) and serial killing, including spheroid and organoid targets; antigen-specific T cell assays (peptide, tetramer and dextramer); metabolic assays (Seahorse, SCENITH); dose-response analysis.
Preclinical models
Syngeneic and humanised tumour models; LCMV acute and chronic infection; adoptive transfer; knockout and reporter lines; in vivo imaging (IVIS); study design with power calculation, randomisation and blinding.
Human tissue and culture
Tumour, healthy tissue and PBMC processing; liver and intraepithelial lymphocyte isolation; air–liquid interface organoids and tissue fragment cultures; STR and mycoplasma QC.
Molecular methods
DNA and RNA extraction, PCR and qPCR, genotyping; Western blot, ELISA, ELISpot.

Immunology focus

Cells
NK cells and innate lymphoid cells; unconventional T cells (MAIT, NKT, γδ and intraepithelial); CD8 and CD4 T cells.
Cancer and therapy
Tumour microenvironment and T cell exhaustion; checkpoint blockade; adoptive cell therapy (TIL, CAR-T, CAR-NK, TCR-engineered T cells); innate immunotherapy; biomarkers of response.
Infection and tissue
LCMV, EBV, CMV and influenza immunity; tissue-resident and liver immunity; type I interferon signalling; immunometabolism; thymic development.

Cell therapy track record